ArticleESMO real world data and digital oncology2026
Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer.
A F Henriksen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.